MedTrace Logo

Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study

NCT05191225 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2022-03-31

No results posted yet for this study

Summary

The objective of this pilot study is therefore to assess the safety of Truxima ultrafast infusion within 30 minutes in patients with non-Hodgkin's lymphoma.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

RiTUXimab Injection [Truxima]

375 (mg/m2) / 60 minutes

DRUG

RiTUXimab Injection [Truxima]

375 (mg/m2) / 30 minutes

Sponsors & Collaborators

  • Laida Cuevas Palomares

    lead NETWORK

Principal Investigators

  • Laida Cuevas Palomares · Bioaraba Health Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-28
Primary Completion
2022-03-31
Completion
2022-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05191225 on ClinicalTrials.gov